Margins matter. The more Antares Pharma (Nasdaq: ATRS ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Antares Pharma's competitive position could be.
Here's the current margin snapshot for Antares Pharma over the trailing 12 months: Gross margin is 55.7%, while operating margin is -29.2% and net margin is -29.2%.
Unfortunately, a look at the most recent numbers doesn't tell us much about where Antares Pharma has been, or where it's going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units while keeping costs in check, its profitability increases. Conversely, a company with gross margins that inch downward over time is often losing out to competition, and possibly engaging in a race to the bottom on prices. If it can't make up for this problem by cutting costs -- and most companies can't -- then both the business and its shares face a decidedly bleak outlook.
Of course, over the short term, the kind of economic shocks we recently experienced can drastically affect a company's profitability. That's why I like to look at five fiscal years' worth of margins, along with the results for the trailing 12 months, the last fiscal year, and last fiscal quarter (LFQ). You can't always reach a hard conclusion about your company's health, but you can better understand what to expect, and what to watch.
Here's the margin picture for Antares Pharma over the past few years.
Source: S&P Capital IQ. Dollar amounts in millions. FY = fiscal year. TTM = trailing 12 months.
Because of seasonality in some businesses, the numbers for the last period on the right -- the TTM figures -- aren't always comparable to the FY results preceding them. To compare quarterly margins to their prior-year levels, consult this chart.
Source: S&P Capital IQ. Dollar amounts in millions. FQ = fiscal quarter.
Here's how the stats break down:
- Over the past five years, gross margin peaked at 74.5% and averaged 62.9%. Operating margin peaked at -27.0% and averaged -98.8%. Net margin peaked at -26.7% and averaged -106.3%.
- TTM gross margin is 55.7%, 720 basis points worse than the five-year average. TTM operating margin is -29.2%, 6,960 basis points better than the five-year average. TTM net margin is -29.2%, 7,710 basis points better than the five-year average.
With recent TTM operating margins exceeding historical averages, but net margins still negative, Antares Pharma still has some work to do.
Looking for alternatives to Antares Pharma? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.